Stock Taper
SCREENER COMPARE ANY 2 STOCKS
FATE
FATE THERAPEUTICS, INC.
NASDAQ
$2.43
▼ DOWN 4.33% (-0.11)

KEY STATISTICS

Market Cap$283.24 M
52w High$3.23
52w Low$0.93
Dividend Yield—
Frequency—
P/E-2.23
Volume709.80K
Shares Out.116.56M

COMPANY

LEADERSHIP

Bahram Valamehr
CHIEF EXECUTIVE
Bahram Valamehr

COMPENSATION 2026

Salary$600,000
Stock Awards$0
Incentive Plan Pay$360,000
All Other Comp.$4,700
Total$2,248,568

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 1, 2013
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
161

PRICE TARGET

Target High$8.00
Target Low$3.50
Target Median$5.50
Target Consensus$5.63

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$1.30M
NOV
12
THU

PRICE

$2.43 ▼ DOWN 4.33% (−$0.11)
$2.44$2.48$2.529:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.43

About Fate Therapeutics, Inc.

https://www.fatetherapeutics.com ↗

Fate Therapeutics, Inc. is a San Diego-based clinical-stage biopharmaceutical company developing programmed NK- and T-cell immunotherapies for cancer and immune disorders, with multiple programs and collaborations worldwide.

INDUSTRY

Biotechnology

A SERVICE FATE THERAPEUTICS, INC. IS KNOWN FOR

FT819 Clinical Program

Fate Therapeutics is developing FT819, an off-the-shelf iPSC-derived CAR T-cell therapy targeting autoimmune diseases like SLE, aiming to offer a readily available, advanced treatment option.

COMPETITORS

COMPETITOR
ALLO COMPARE
ATRA COMPARE
CRBU COMPARE
CRSP COMPARE
NKTX COMPARE

Revenue by Products

IconPRODUCTQ1-2023Q2-2023Q3-2023Q4-2023
Upfront Fee And Equity Premium$31.2M $31.2M $31.2M $0 ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
33
LISTED HERE
8
RANKED BY POSITION SIZE
VTS.AX
0.00% · 3.2M
SCHA
0.01% · 502.2K
IWC
0.07% · 395.1K
PRFZ
0.02% · 227.5K
AVSC
0.01% · 127.9K
DFMC
0.00% · 82.1K
CN
CNCR
3.33% · 17.7K
JHMH
0.10% · 548

INSTITUTIONAL OWNERSHIP

SHARES OWNED
66.58%
HOLDERS
257
TOP 12 OF 257 · RANKED BY POSITION SIZE
Redmile Group, LLC
12.9M sh · $16.22M
Blackrock, Inc.
10.7M sh · $13.46M
Blackrock Inc.
10.1M sh · $33.18M
Vanguard Group Inc
9.0M sh · $8.82M
Wilshire Advisors LLC
8.5M sh · $10.69M
Boxer Capital, LLC
5.0M sh · $17.36M
Acadian Asset Management LLC
4.4M sh · $11.74M
Aqr Capital Management LLC
3.8M sh · $10.36M
Two Sigma Investments, LP
3.6M sh · $9.69M
Johnson & Johnson Innovation - Jjdc, Inc.
3.4M sh · $293.27M
Johnson & Johnson
3.4M sh · $9.12M
Renaissance Technologies LLC
3.0M sh · $8.05M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book3
Overall Score1

TRADES BY CONGRESS

HOUSE TRADES
Daniel Goldman
Daniel Goldman
Sale
2023-01-31

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Valamehr Bahram
Sale · 43.9K shares
2026-08-04
★
OFFICER: SEE REMARKS
TAHL CINDY
Sale · 38.8K shares
2026-08-04
★
DIRECTOR
Jooss Karin
Purchase · 87.9K shares
2026-06-12
★
DIRECTOR
Lee Michael Stewart
Purchase · 87.9K shares
2026-06-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
EQUAL WEIGHT 1
OVERWEIGHT 1
OUTPERFORM 1
BUY 1
HOLD 1
5 GRADES IN THE LAST 12 MONTHS
Wells Fargo EQUAL WEIGHT Piper Sandler OVERWEIGHT Wedbush OUTPERFORM HC Wainwright & Co. BUY Needham HOLD

SECTORS PEERS

PEERPRICE
VOR$22.65COMPARE
PRLD$5.47COMPARE
ALEC$2.34COMPARE
PEPG$3.08COMPARE
ABOS$2.92COMPARE
CRBP$10.91COMPARE
NKTX$2.76COMPARE
MOLN$4.50COMPARE